« Itax (Itopride) Fails Phase III Clinical Trials, Axcan Pharma Shares Fall | Main | MannKind Corp.’s Technosphere® Insulin System, Showed Safety and Efficacy in Phase III Clinical Trial in Type 2 Diabetes Patients »

Sep25
CoFactor®/ Uftoral® (UFT) Combination Showed Positive Results in Colorectal Cancer Model

Treatment of metastatic colorectal cancer in mice with CoFactor® in combination with Uftoral® (UFT) as demonstrated by clinical data recently reported by ADVENTRX Pharmaceuticals, Inc. (Amex: ANX).

CoFactor® is a folate-based drug designed to improve the efficacy and safety of the anticancer agent 5-fluorouracil (5-FU) while UFT is an oral anticancer drug approved for use in Asia and Europe that delivers a combination of tegafur, a prodrug of 5-FU, and uracil.

According to Evan M. Levine, ADVENTRX Pharmaceuticals, Inc.’s CEO:

"These CoFactor/UFT results are further evidence of CoFactor's improved ability over leucovorin to potentiate the efficacy of fluoropyrimidines. Results from numerous preclinical studies with and without the addition of oxaliplatin, anti-VEGF or gemcitabine suggest that CoFactor is more effective than leucovorin at modulating 5-FU, thereby increasing inhibition of tumor growth in colorectal, gastric and pancreatic tumor models while demonstrating reduced toxicity."

These results were presented as an abstract entitled: "5,10 Methylenetetrahydrofolate (CoFactor) Enhances UFT Antitumor Activity Against Human Colorectal HT-29 Tumor Xenografts in Nude Mice", at a joint meeting of the 7th International Conference of Asian Clinical Oncology Society (ACOS) & the 9th Annual Meeting of Chinese Society of Clinical Oncology (CSCO) held September 16, 2006 in Beijing, China.

Find more details of the study in the press release.

related entries


0 Comments/Trackbacks




submit a trackback

TrackBack URL for this entry:

post a comment

Name, Email Address, and URL are not required fields.





Comment Preview

« Itax (Itopride) Fails Phase III Clinical Trials, Axcan Pharma Shares Fall | Main | MannKind Corp.’s Technosphere® Insulin System, Showed Safety and Efficacy in Phase III Clinical Trial in Type 2 Diabetes Patients »

Advertise

Watch the Digital Health Revolution


Related Resources

recent comments

    sponsored ads



    subscribe


    Prefer Email?
    Subscribe below-

    Enter your Email:


    Powered by FeedBlitz What's this?

    Current News

    Support This Blog

    blogroll


    top blogs

    business social media

    Use these fast growing business social media sites to promote your business, feature your products, spotlight your business leaders, create links, and drive traffic back to your company site, all for free!

    BIZZlogos - Add your logo - free link to your site
    BIZZphotos - Add photos of your products and people
    BIZZprofiles - Submit your profile and build your online visibility
    BIZZspotlight - Spotlight your business with free links
    BIZZvideos - Videos about businesses, products and business people.
    BIZZbites - "Digg" for Business - Submit your articles and posts

    Know More Media - Health Care / Pharmaceutical / Fitness

    know more media network

    View Network Map

    Network Feed List (OPML)

    Know More Media Network
    Feed


    we support unitus

    PRWeb

    Influencer



    PharmaGazette is a member of the Know More Media network of business related blogs.

    Here are some current headlines from some of our business publications:

    ProductivityGoal

    CallCenterScript

    AdHurl

    TheBizofKnowledge

    LandingTheDeal

    CustomersAreAlways

    HealthCareVox

    BrainBasedBusiness

    TheInsurancePolicy

    MarketingBlurb